🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

GridAI Technologies Corp. GRDX PHARMA

Healthcare · Biotechnology · United Kingdom
https://www.grid-ai.com
Company Profile ↓
$3.20
+70.39% 1Y
Mkt Cap$22.82M
P/E-0.50
52W High$6.80
52W Low$1.83
EPS (TTM)$-6.41

Company Overview

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 18.8% per year over the last five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.12.

Recent Developments

  • 5-Year Trend Long-term compounding — profit CAGR 18.8%.

Growth & Price Performance

Compounded Profit Growth

5 Years:18.77%
1 Year:-

Stock Price Performance

1 Year:+70.39%
6 Months:+50.23%
3 Months:-48.55%
1 Month:+16.79%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 28% of range
$1.83 $6.80
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)42.57 · Neutral
Price Performance
1M+16.79%
3M-48.55%
6M+50.23%
1Y+70.39%

Auto-generated from price history and fundamentals; not investment advice.

Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 18.8% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 52.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Ad space

Valuation

Stock P/E
-0.50
Industry PE
24.83
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
530.76
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
18.77%
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-21.21%
ROE
-25.63%
ROA
-13.17%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.82
EPS (TTM)
$-6.41

Balance Sheet & Liquidity

Debt/Equity
0.12
Quick Ratio
-
Current Ratio
0.16
Debt
$2.59M
Total Assets
$47.97M
Current Assets
$2.58M
Working Capital
$-13.65M

Ownership

Promoter Holding
12.08%
Chg in Prom Hold
-0.66%
FII / Inst Holding
8.98%
Chg in FII Hold
-0.49%

Financial Snapshot

Enterprise Value
$22.82M
Total Revenue (TTM)
$36.25K
EBITDA
$-6.51M
Free Cash Flow
$-32.36M
Operating Cash Flow
$-5.70M
Shares Outstanding
7.13M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GRDX GridAI Technologies Corp. PHARMA 3.20 -0.50 $22.82M 0.00% -21.21% -25.63% - 18.77%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------------------------38.21K
Gross Profit --------------------------------613.74K
Operating Income -1.41M-1.35M-1.72M-2.19M-2.81M-2.38M-2.73M-3.58M-3.26M-2.57M-4.60M-4.93M-4.08M-2.93M-2.39M-3.71M-8.21M-9.28M-30.40M-9.38M-5.41M4.39M-4.06M-4.18M-3.43M-9.10M-3.43M-1.89M-821.39K-638.86K-934.79K-3.61M
Net Income -1.87M-1.99M-3.77M-3.20M-2.81M-2.67M-3.13M-3.63M-3.31M-2.57M-4.66M-5.04M-4.19M-5.26M-4.70M-5.31M-7.69M-9.28M-30.40M-9.63M-5.41M4.39M-4.07M-4.19M-3.43M5.57M-8.81M-2.58M-1.26M-998.27K-1.15M-
Diluted EPS -----------------5.42-1.63-98.00-138.28-53.4718.23-36.46-37.73-9.210.38-3.86-1.76-0.84-0.21-0.75-0.82
R&D Expense 364.00K685.58K840.66K744.31K534.14K743.42K966.68K1.68M925.78K1.17M3.01M2.88M2.22M1.55M1.09M1.80M2.52M5.65M3.05M4.98M2.91M791.07K1.36M1.35M1.01M554.66K219.59K207.00K15.83K10.63K6.67K631.38K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---00--00036.25K
Cost of Revenue ---------0693.68K
Gross Profit ---------0-657.43K
Operating Expenses -------12.68M15.77M15.62M6.43M
Operating Income -4.73M-6.33M-10.22M-13.43M-14.74M-26.43M--12.68M-15.77M-15.62M-7.08M
EBITDA --------14.58M-15.74M-15.57M-6.51M
Interest Expense ------11.23K15.88K22.46K--
Pretax Income --------14.63M-15.79M-15.62M-6.64M
Tax Provision ---------0-398.74K
Net Income -5.93M-14.59M-11.10M-13.53M-15.18M-32.67M--14.63M-15.79M-18.06M-6.39M
Diluted EPS ------14.68--1,250.82-143.64-15.99-4.16
R&D Expense 1.40M2.50M2.40M5.77M8.68M5.89M16.99M8.78M5.03M903.94K925.48K

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Sep 2021Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -6.69M6.75M5.48M7.47M8.90M12.92M-11.79M5.44M6.88M85.41M48.55M
Total Equity 2.64M-3.63M3.21M1.66M4.47M4.62M-2.64M6.97M-7.82M2.74M3.60M-3.88M24.94M
Cash & Equivalents ------6.06M-8.25M1.36M3.71M163.48K899.78K
Total Liabilities -10.32M3.54M3.82M3.00M4.29M15.56M-19.61M2.70M3.28M27.61M19.72M
Current Liabilities -8.82M2.34M2.48M3.00M4.29M15.55M-12.30M2.48M3.13M27.55M15.16M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.17M-4.53M-7.18M-10.87M-14.03M-11.22M-32.29M-22.34M-12.38M-9.22M-5.70M
Investing Cash Flow -24.38K-12.36K-32.17K-305.47K-24.10K87.35K-10.32M--500.00K88.17K323.48K
Financing Cash Flow 4.68M5.75M6.01M11.71M13.14M17.05M44.76M15.74M15.23M5.58M5.89M
Capital Expenditure ---32.17K-55.47K-24.10K-4.17K-69.49K----
Free Cash Flow ---7.22M-10.92M-14.06M-11.23M-32.36M----

Ratios (Annual)

Figures in %.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------1,813.6%
Operating Margin % -----------19,540.0%
Net Margin % -----------17,634.4%
ROE % 163.4%-454.1%-668.2%-302.5%-328.7%1,237.2%--533.5%-438.4%465.8%-25.6%
ROCE % 222.0%-143.3%-340.6%-300.2%-319.3%1,008.3%--428.9%-420.6%-27.0%-21.2%

Shareholding Pattern

Insiders
12.08%
Institutions
8.98%
Public Float
10.22%

Top Institutional Holders

#Holder% HeldSharesValue
1 Renaissance Technologies, LLC 2.47% 176.30K $548.29K
2 Citadel Advisors Llc 1.20% 85.33K $265.36K
3 Federation Des Caisses Desjardins Du Quebec 1.07% 76.35K $237.45K
4 Vanguard Capital Management LLC 1.04% 74.06K $230.33K
5 Geode Capital Management, LLC 0.84% 59.90K $186.28K
6 Jane Street Group, LLC 0.69% 49.24K $153.12K
7 Vanguard Fiduciary Trust Co 0.47% 33.80K $105.13K
8 State Street Corporation 0.33% 23.45K $72.92K
9 HRT Financial LP 0.29% 20.96K $65.19K
10 Independent Advisor Alliance 0.21% 15.00K $46.65K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GRDX

Google News Fri, 14 Aug 2026

GridAI Technologies Corp. (GRDX) uses Rule 12b-25 for brief Q2 10-Q delay - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZ2I2bUE1VmFOZXRHaTB3MDVuRDgzZkUxdHl4WUV5XzlEWUxMamo5bUZrT29yTEVQOU9ubEpvOFZOMENLNTQ5Zy1WblJNQ3BXWXdzaWFmcjBhTl9IVlg5bDRCVHhQRDBmZC1iTkJmMTFmUjd3Zmx2SFc3TF94VmEzbmZORDg1c3V4VHdZTD…

Google News hu, 03 Sep 2026

Enterprise value to EBIT forward of GridAI Technologies Corp. – NASDAQ:GRDX - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMUxrRDhwSjE1bjRPYVFEXzBvN01sTElpSGZ3SHJNMGlPTjNSeVpXSE9mRDB4RTRyYWMyc1pBZUwyTzBnOWlsMHhwVGVVLXk3ZzdYOFVfNnpjcFhFeU5wdzRjYWl0TExKWEhHU3ZFMDBkdkhEb0h3TUR5TXhrYUF2aFZQY3ZFYWdwZVpJeH…

Google News Wed, 03 Dec 2025

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBJQkhEb196am9TOEE2S0cwb2ZMYU0wNnV3MVd1QzJydVBoak53eFNtaV9RNW45OGRkUVdYajB3V0kyV2lNNTdUbnc0MFVNbUlK?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>&nbsp;&nbsp;<fon…

Google News ue, 01 Sep 2026

GridAI Technologies Corp. (NASDAQ: GRDX) Stock Price, News & Analysis - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE04WWdwSm95YVJsWDhBel9peXlBcFNDRzJBb2RqdWV0WFJBN2VTMVRGelBEWHJYQnZaczRGLUlKZlJZajBnbnRVWU54QnN4THg3RGpxSDdB?oc=5" target="_blank">GridAI Technologies Corp. (NASDAQ: GRDX) Stock Pric…

Google News ue, 26 May 2026

GRDX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5uR1J5Y282Wk9kLXU0a3NDWS1WVjRxSGxpczNYbU9hdm9aaFl3bGQ0NFNaVEJfWnIzQ0lYS2YxQk55dEp6c2c?oc=5" target="_blank">GRDX</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Fri, 21 Aug 2026

GridAI Technologies Corp. (NASDAQ: GRDX) Stock Price, News & Analysis - kalkine.ca

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9nSzRrLWR4eVhYbXBkVTNqT0VPcjZmRGo3OEt3cFVKYVpDLUtmcGtUd2Q5TEZjcExnck5lcHVHbF9JSFlSTF8wYjJIYzVGR09x?oc=5" target="_blank">GridAI Technologies Corp. (NASDAQ: GRDX) Stock Price, News …

GRDX — Frequently Asked Questions

What is the current share price of GridAI Technologies Corp. (GRDX)?

As of 2026-09-19 21:16 PDT, GridAI Technologies Corp. (GRDX) trades at $3.20 on NasdaqCM. Its 52-week range is $1.83 to $6.80.

What is the market capitalisation of GRDX?

GridAI Technologies Corp. (GRDX) has a market capitalisation of $22.82M on NasdaqCM.

What is the P/E ratio of GRDX?

GRDX trades at a trailing price-to-earnings (P/E) ratio of -0.50. The industry average P/E is 24.83.

What is the return on equity (ROE) of GRDX?

GRDX has a return on equity (ROE) of -25.63%. Its return on capital employed (ROCE) is -21.21%.

Is GRDX a good stock to buy?

This page provides a data-driven analysis of GridAI Technologies Corp. (GRDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks